Cargando…

Overall survival of individuals with metastatic cancer in Sweden: a nationwide study

AIMS: Consistent improvements for overall survival (OS) have been reported for individuals with metastatic cancer. Swedish population-based registers allow national coverage and long follow-up time. The aim of this study was to estimate and explore long-term OS of individuals diagnosed with metastat...

Descripción completa

Detalles Bibliográficos
Autores principales: Bütepage, Greta, Carlqvist, Peter, Jacob, Johanna, Toft Hornemann, Asbjørn, Vertuani, Simona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563107/
https://www.ncbi.nlm.nih.gov/pubmed/36229841
http://dx.doi.org/10.1186/s12889-022-14255-w
_version_ 1784808324760338432
author Bütepage, Greta
Carlqvist, Peter
Jacob, Johanna
Toft Hornemann, Asbjørn
Vertuani, Simona
author_facet Bütepage, Greta
Carlqvist, Peter
Jacob, Johanna
Toft Hornemann, Asbjørn
Vertuani, Simona
author_sort Bütepage, Greta
collection PubMed
description AIMS: Consistent improvements for overall survival (OS) have been reported for individuals with metastatic cancer. Swedish population-based registers allow national coverage and long follow-up time. The aim of this study was to estimate and explore long-term OS of individuals diagnosed with metastatic cancer using Swedish nationwide health registers. METHODS: Individuals with metastatic breast (MBC), non-small cell lung (MNSCLC), ovary (MOC) or colorectal cancer (MCRC) or metastatic malignant melanoma (MMM) were identified in the Swedish national cancer register and national patient registers. Survival was estimated and stratified by available variables. Potential cure fractions were estimated using mixture cure models. RESULTS: In total, approximately 69,000 individuals were identified. The most common cancers were MCRC (36.2%) and MNSCLC (29.5%). Men were more frequently diagnosed with MNSCLC, MCRC, and MMM compared to women. Except for MOC, about 50% of individuals were 70 years or older at diagnosis. Throughout the study period survival differed across cancers. The longest median OS was observed for individuals with MOC and MBC. At 10 years of follow-up, the survival curves flatten at a survival rate of approximately 10% for all cancers except MNSCLC. The youngest age groups had the longest median OS. Increased survival was also observed for individuals diagnosed in 2015 and 2018 compared to individuals diagnosed during earlier years. The estimated cure fractions were 4% for MBC, 1.5% for MNSCLC, 6.8% for MCRC, 8.6% for MOC and MMM. CONCLUSIONS: Long-term survival has been assessed across all indications except for NSCLC.. The findings may be relevant for healthcare planning to meet the needs of future patients and potential long-term survivors. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12889-022-14255-w.
format Online
Article
Text
id pubmed-9563107
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-95631072022-10-15 Overall survival of individuals with metastatic cancer in Sweden: a nationwide study Bütepage, Greta Carlqvist, Peter Jacob, Johanna Toft Hornemann, Asbjørn Vertuani, Simona BMC Public Health Research AIMS: Consistent improvements for overall survival (OS) have been reported for individuals with metastatic cancer. Swedish population-based registers allow national coverage and long follow-up time. The aim of this study was to estimate and explore long-term OS of individuals diagnosed with metastatic cancer using Swedish nationwide health registers. METHODS: Individuals with metastatic breast (MBC), non-small cell lung (MNSCLC), ovary (MOC) or colorectal cancer (MCRC) or metastatic malignant melanoma (MMM) were identified in the Swedish national cancer register and national patient registers. Survival was estimated and stratified by available variables. Potential cure fractions were estimated using mixture cure models. RESULTS: In total, approximately 69,000 individuals were identified. The most common cancers were MCRC (36.2%) and MNSCLC (29.5%). Men were more frequently diagnosed with MNSCLC, MCRC, and MMM compared to women. Except for MOC, about 50% of individuals were 70 years or older at diagnosis. Throughout the study period survival differed across cancers. The longest median OS was observed for individuals with MOC and MBC. At 10 years of follow-up, the survival curves flatten at a survival rate of approximately 10% for all cancers except MNSCLC. The youngest age groups had the longest median OS. Increased survival was also observed for individuals diagnosed in 2015 and 2018 compared to individuals diagnosed during earlier years. The estimated cure fractions were 4% for MBC, 1.5% for MNSCLC, 6.8% for MCRC, 8.6% for MOC and MMM. CONCLUSIONS: Long-term survival has been assessed across all indications except for NSCLC.. The findings may be relevant for healthcare planning to meet the needs of future patients and potential long-term survivors. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12889-022-14255-w. BioMed Central 2022-10-14 /pmc/articles/PMC9563107/ /pubmed/36229841 http://dx.doi.org/10.1186/s12889-022-14255-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Bütepage, Greta
Carlqvist, Peter
Jacob, Johanna
Toft Hornemann, Asbjørn
Vertuani, Simona
Overall survival of individuals with metastatic cancer in Sweden: a nationwide study
title Overall survival of individuals with metastatic cancer in Sweden: a nationwide study
title_full Overall survival of individuals with metastatic cancer in Sweden: a nationwide study
title_fullStr Overall survival of individuals with metastatic cancer in Sweden: a nationwide study
title_full_unstemmed Overall survival of individuals with metastatic cancer in Sweden: a nationwide study
title_short Overall survival of individuals with metastatic cancer in Sweden: a nationwide study
title_sort overall survival of individuals with metastatic cancer in sweden: a nationwide study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563107/
https://www.ncbi.nlm.nih.gov/pubmed/36229841
http://dx.doi.org/10.1186/s12889-022-14255-w
work_keys_str_mv AT butepagegreta overallsurvivalofindividualswithmetastaticcancerinswedenanationwidestudy
AT carlqvistpeter overallsurvivalofindividualswithmetastaticcancerinswedenanationwidestudy
AT jacobjohanna overallsurvivalofindividualswithmetastaticcancerinswedenanationwidestudy
AT tofthornemannasbjørn overallsurvivalofindividualswithmetastaticcancerinswedenanationwidestudy
AT vertuanisimona overallsurvivalofindividualswithmetastaticcancerinswedenanationwidestudy